SpringWorks Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
SpringWorks Therapeutics CEO'su Saqib Islam, Jul2018 tarihinde atandı, in görev süresi 6.33 yıldır. in toplam yıllık tazminatı $ 18.35M olup, şirket hissesi ve opsiyonları dahil olmak üzere 4% maaş ve 96% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.93% ine doğrudan sahiptir ve bu hisseler $ 27.05M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.5 yıl ve 5.3 yıldır.
Anahtar bilgiler
Saqib Islam
İcra Kurulu Başkanı
US$18.4m
Toplam tazminat
| CEO maaş yüzdesi | 4.0% |
| CEO görev süresi | 6.3yrs |
| CEO sahipliği | 0.9% |
| Yönetim ortalama görev süresi | 4.5yrs |
| Yönetim Kurulu ortalama görev süresi | 5.3yrs |
Son yönetim güncellemeleri
Recent updates
Here's What Analysts Are Forecasting For SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) After Its Third-Quarter Results
Nov 15
SpringWorks Therapeutics Merits A Speculative Buy
Nov 04SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
Aug 07Need To Know: Analysts Are Much More Bullish On SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Revenues
May 11We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
May 03SpringWorks Therapeutics: Newly Commercial Stage, Fully Valued Biotech Means Steer Clear
Apr 25SpringWorks Therapeutics: Multiple Opportunities, But No Sure-Fire Winners
Apr 19We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Sep 20We're Not Very Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Rate
Jun 07We Think SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Drive Business Growth
Feb 22Here's Why We're Not Too Worried About SpringWorks Therapeutics' (NASDAQ:SWTX) Cash Burn Situation
Nov 09SpringWorks drops 21% as Allogene drops lead asset in combination study
Aug 10SpringWorks Therapeutics GAAP EPS of -$1.41 misses by $0.15
Aug 04Sizing Up SpringWorks Therapeutics
Jul 20Will SpringWorks Therapeutics (NASDAQ:SWTX) Spend Its Cash Wisely?
Jun 06SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
May 02Companies Like SpringWorks Therapeutics (NASDAQ:SWTX) Can Afford To Invest In Growth
Dec 30SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Dec 14SpringWorks Therapeutics (NASDAQ:SWTX) Is In A Strong Position To Grow Its Business
Sep 15CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$275m |
| Jun 30 2024 | n/a | n/a | -US$301m |
| Mar 31 2024 | n/a | n/a | -US$339m |
| Dec 31 2023 | US$18m | US$725k | -US$325m |
| Sep 30 2023 | n/a | n/a | -US$305m |
| Jun 30 2023 | n/a | n/a | -US$298m |
| Mar 31 2023 | n/a | n/a | -US$289m |
| Dec 31 2022 | US$15m | US$680k | -US$277m |
| Sep 30 2022 | n/a | n/a | -US$259m |
| Jun 30 2022 | n/a | n/a | -US$228m |
| Mar 31 2022 | n/a | n/a | -US$206m |
| Dec 31 2021 | US$18m | US$590k | -US$174m |
| Sep 30 2021 | n/a | n/a | -US$107m |
| Jun 30 2021 | n/a | n/a | -US$87m |
| Mar 31 2021 | n/a | n/a | -US$60m |
| Dec 31 2020 | US$8m | US$541k | -US$46m |
| Sep 30 2020 | n/a | n/a | -US$73m |
| Jun 30 2020 | n/a | n/a | -US$68m |
| Mar 31 2020 | n/a | n/a | -US$62m |
| Dec 31 2019 | US$3m | US$480k | -US$51m |
| Sep 30 2019 | n/a | n/a | -US$41m |
| Jun 30 2019 | n/a | n/a | -US$29m |
| Mar 31 2019 | n/a | n/a | -US$18m |
| Dec 31 2018 | US$2m | US$407k | -US$18m |
Tazminat ve Piyasa: Saqib 'nin toplam tazminatı ($USD 18.35M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 6.56M ).
Tazminat ve Kazançlar: Saqib şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.
CEO
Saqib Islam (54 yo)
6.3yrs
Görev süresi
US$18,351,489
Tazminat
Mr. Saqib Islam, J.D. has been Chief Executive Officer and Director at SpringWorks Therapeutics, Inc. since August 2018. He serves as an Independent Director of Passage Bio, Inc. since March 2019. Mr. Isla...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 27.1m | |
| Chief Financial Officer | 5.3yrs | US$3.74m | 0.025% $ 729.2k | |
| Chief Operating Officer | 3.8yrs | US$6.64m | 0.21% $ 6.1m | |
| Chief Medical Officer | 3.3yrs | US$4.31m | 0.031% $ 900.4k | |
| Chief Accounting Officer | 4.7yrs | Veri yok | 0.0083% $ 240.3k | |
| Chief Scientific Officer | 1.2yrs | Veri yok | 0.0075% $ 218.5k | |
| Vice President of Communications & Investor Relations | 6.8yrs | Veri yok | Veri yok | |
| General Counsel & Secretary | 4.8yrs | US$2.83m | 0.018% $ 531.6k | |
| Chief People Officer | 4.3yrs | US$2.52m | 0.0065% $ 188.6k | |
| Chief Commercial Officer | 3.7yrs | US$4.94m | 0.014% $ 400.4k |
4.5yrs
Ortalama Görev Süresi
56yo
Ortalama Yaş
Deneyimli Yönetim: SWTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.5 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| CEO & Director | 6.3yrs | US$18.35m | 0.93% $ 27.1m | |
| Independent Director | 5.3yrs | US$520.14k | 0.014% $ 412.6k | |
| Independent Chairman of the Board | 8.8yrs | US$545.14k | 0.41% $ 11.8m | |
| Director | less than a year | Veri yok | Veri yok | |
| Independent Director | 7.3yrs | US$508.45k | 0.014% $ 412.6k | |
| Independent Director | 2.3yrs | US$507.64k | 0.011% $ 312.2k | |
| Independent Director | 4.5yrs | US$520.14k | Veri yok |
5.3yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: SWTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.3 yıldır).